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Abstract
Background: Osteosarcoma is a very aggressive tumor with a propensity to metastasize and invade surrounding tissue.
Identification of the molecular determinants of invasion and metastatic potential may guide the development of a rational
strategy for devising specific therapies that target the pathways leading to osteosarcoma.
Methods: In this study, we used pathway-focused low density expression cDNA arrays to screen for candidate genes related
to tumor progression. Expression patterns of the selected genes were validated by real time PCR on osteosarcoma patient
tumor samples and correlated with clinical and pathological data.
Results: THBS3, SPARC and SPP1 were identified as genes differentially expressed in osteosarcoma. In particular, THBS3 was
expressed at significantly high levels (p = 0.0001) in biopsies from patients with metastasis at diagnosis, which is a predictor of
worse overall survival, event-free survival and relapse free survival at diagnosis. After chemotherapy, patients with tumors over-
expressing THBS3 have worse relapse free survival. High SPARC expression was found in 51/55 (96.3%) osteosarcoma samples
derived from 43 patients, and correlated with the worst event-free survival (p = 0.03) and relapse free survival (p = 0.07).
Overexpression of SPP1 was found in 47 of 53 (89%) osteosarcomas correlating with better overall survival, event-free survival
and relapse free survival at diagnosis.
Conclusion: In this study three genes were identified with pattern of differential gene expression associated with a phenotypic
role in metastasis and invasion. Interestingly all encode for proteins involved in extracellular remodeling suggesting potential
roles in osteosarcoma progression. This is the first report on the THBS3 gene working as a stimulator of tumor progression.
Higher levels of THBS3 maintain the capacity of angiogenesis. High levels of SPARC are not required for tumor progression but
are necessary for tumor growth and maintenance. SPP1 is not necessary for tumor progression in osteosarcoma and may be
associated with inflammatory response and bone remodeling, functioning as a good biomarker.
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Background
Osteosarcoma (OS) is a rare tumor of children and young
adults. The peak of incidence occurs in the second decade
of life [1]. In Brazil, it is estimated that a total of 350 new
cases of OS are diagnosed per year [2], with metastasis in
20.9% of the cases. The presence of metastases at diagno-
sis is the most significant isolated factor influencing sur-
vival in this group [3]. Lung metastases appear in almost
40 to 50% of the patients with OS, and are the major
cause of death [4]. The degree of necrosis following defin-
itive surgery is a consistent prognostic factor [5].
Metastases consist of a series of sequential steps, all of
which must be successfully completed. These include
shedding of cells from a primary tumor into the circula-
tion, survival of the cells in the circulation, arrest in a new
organ, extravasations into the surrounding tissue, initia-
tion and maintenance of growth, and vascularization of
the metastatic tumor [6]. The successful metastatic cells
must possess a set of particular characteristics that are dif-
ferent from non-metastatic tumor cells, enabling them to
complete each step in the metastatic sequence [7].
Knowledge on the biology of the metastatic process is lim-
ited. Some molecular factors have been identified as con-
tributing to the formation of detectable metastases, and
additional factors hopefully will be soon identified using
microarray expression profiling [6]. The pathway-focused
GEArray® is a useful way to perform both highly sensitive
and precise large-scale analysis of the expression level of
various genes [8,9]. The advantage of using this technol-
ogy is that a defined set of genes closely-related to a spe-
cific process, biological behavior or biomarker can be
screened with limited sample material, as observed by
[10-12]. Through these comparisons, a list of genes differ-
entially expressed and potentially important for the proc-
ess is easily derived that can be validated by other
techniques. The biomarkers may become tools for estab-
lishing early diagnosis and designing therapeutic targets
in specific cancers.
By comparing the highly metastatic K7M2 and K12
murine osteosarcoma cell lines using cDNA microarray
technology, Khanna et al. [13] identified 10 potential
genes involved in the metastatic process in osteosarcoma:
ITGB4 (integrin β4), CTGF (connective tissue growth fac-
tor), ITGA5 (integrin α5), VIL2 (ezrin), ITGB2 (integrin
β2), LGALS3 (galectin-3), ADAM8 (a disintegrin and met-
alloprotease domain 8), CLU (clusterin), FARP1 (FERM,
RhoGEF, and pleckstrin domain protein 1 isoform 1) and
CP (ceruloplasmin). These genes are involved in motility/
cytoskeleton, heterotypic adherence and/or angiogenesis
[13].
Genes identified in this work include those not described
previously in OS as well as potentially novel metastasis-
associated genes. Functional studies suggest that 10 genes
associated with motility/cytoskeleton, heterotypic adher-
ence, and angiogenesis are most likely associated with dif-
ferences in the metastatic behavior of the high and low
metastatic OS models.
In this study, we used the pathway-focused GEArray® tech-
nique to screen genes related to tumor progression.
THBS3, SPARC and SPP1 were identified by cDNA array as
genes differentially expressed in osteosarcoma. In addi-
tion, expression of selected genes was significantly corre-
lated with clinico-pathological data.
Methods
Sample collection
Seventy-six OS tumor samples were obtained at the Insti-
tuto de Oncologia Pediátrica, Grupo de Apoio ao Adoles-
cente e à Criança com Câncer/Universidade Federal de
São Paulo (IOP/GRAACC/UNIFESP, São Paulo, SP, Bra-
zil), with informed patient consent and approval of the
institutional research ethics board (0261/03). Tissue sec-
tions were stained and subjected to standard histopatho-
logical evaluation to determine tumor content, as well as
the proportion of necrosis and the pathological grade.
Tumor specimens were stored at -80°C until a tumor-rich
tissue had been selected for RNA extraction, according to
the histological assessment by the pathologist. Clinical
data for each case was obtained from the medical records.
Diagnostic staging and treatment
All patients younger than 25 years of age with high-grade
OS of the extremities (metastatic and non-metastatic)
were prospectively enrolled onto the Brazilian Osteosar-
coma Treatment Group study IV [3]. In study IV, patients
received carboplatin (500 mg/m2 intravenous infusion on
day 1 of weeks 0, 3, 6, 17, and 26) and cisplatin (100 mg/
m2 intravenous infusion on day 1 of weeks 0, 3, 6, 11, and
20). Doxorubicin was administered either at a dose of 30
mg/m2 in short-term intravenous infusion on days 1 and
2 of weeks 0, 3, 6, 14, 17, and 23 in the initial phase of the
study or at a dose of 35 mg/m2, following the same sched-
ule administered in a previous group with dexrazoxane.
Intravenous infusion infusions of ifosfamide at 3 g/m2
and mesna, as described [3] were added on days 1, 2, and
3 and on weeks 11, 14, 20, and 26, respectively. The
orthopedics team in collaboration with the pediatric
oncology team determined the appropriate surgical proce-
dure for each patient. Non-conventional endoprosthesis,
resection of expendable bones, plaques, and bone graft
fixation (autograft or bone bank) were used. Whenever
possible, all pulmonary metastases were surgically
removed, after resection of the primary tumor.BMC Cancer 2006, 6:237 http://www.biomedcentral.com/1471-2407/6/237
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RNA preparation
Total RNA from OS tumors was isolated using the TRIzol®
Reagent (Invitrogen) and re-suspended in sterile DEPC
water. The amount of RNA was determined by spectro-
photometry and sample integrity was monitored through
visualization of ribosomal RNAs (28S and 18S) by elec-
trophoresis.
Gene expression profiling
Pathway-focused expression profiling was performed
using a subset of 15 tumors: 9 samples from patients with
metastatic disease at diagnosis (3 initial biopsy speci-
mens, 3 primary bone tumor resection specimens, and 3
biopsies of metastasis detected at diagnosis); and 6 sam-
ples from patients classed as having non-metastatic dis-
ease at diagnosis (3 initial biopsy specimens and 3
primary bone tumor resection specimens). For each
group, a pool of an equal amount of RNA from 3 tumor
samples from each phase of disease was used. In addition,
a pool of RNA derived from osteoblastic cellular prepara-
tions from two bone resections unrelated to a pathologi-
cal condition served as a tissue-specific expression control.
GEArray® Q Series pathway arrays containing 112 sites
each (3 blanks, 3 negative reference spots, 10 endogenous
genes, and 96 pathway-specific human genes) were
obtained from SuperArray Bioscience Corporation (Fred-
erick, USA). The GEArray® Q Series Human Tumor Metas-
tasis Gene Array, Chemokines and Receptors Gene Array
and Angiogenesis Gene Array were designed to assess the
different expression levels of 96 genes that either interact
with or are controlled by each specific biological pathway.
Protocol and data analysis of arrays were performed
according to the manufacturer's instructions and the gene
list and array position for expression profiling are availa-
ble at Superarray Bioscience Corporation website [14].
Biotin-labeled cDNA were generated with total RNA (1μg)
from corresponding samples using GEArray® Ampolabel-
ling LPR Kit (SuperArray Bioscience Corporation®). The
cDNA probes were then denatured, and hybridized in
GEAhyb solution to nylon membranes spotted with gene-
specific fragments. Hybridization was performed over-
night at 60°C with continuous agitation. Membranes
were washed twice in 2 × SSC/1%SDS for 15 minutes
each, followed by another wash in 0.1 × SSC/0.5%SDS for
15 minutes. Hybridized probes were visualized with the
CPD-Star Chemiluminescent Detection Kit (SuperArray
Bioscience Corporation®).
Array images were recorded using Kodak X-OMAT LS film
(Amersham Biosciences, Piscataway, NJ, USA) and Sprint-
Scan 35 Plus (Polaroid Canada Inc., Mississauga, ON,
Canada). Images were converted into grayscale and 16-bit
tiff format, and the numerical data representing the
expression levels of each gene on the arrays were quanti-
fied using the GEArray® Expression Analysis Suite (Super-
Array Bioscience Corporation®). Raw data were intra-
normalized with the mean signal intensity of the ACTB
gene after subtracting the mean intensities of the negative
control spots (pUC18 plasmid DNA and blank spots.
Inter-normalization was performed with control normal
bone signal intensities.
The change in the level of a given gene transcript from one
membrane/experiment was estimated by comparing the
signal intensities of paired specimens, such as: (1) biopsy
sample from patients with metastasis at diagnosis versus
normal bone; (2) primary tumor resection sample from
patients with metastasis at diagnosis versus normal bone;
(3) metastatic sample from patient with metastasis at
diagnosis versus  normal bone; (4) biopsy sample from
patients with non metastasis at diagnosis versus normal
bone; (5) primary tumor resection sample from patients
with non metastasis at diagnosis versus normal bone. The
differentially expressed genes were determined based on
two criteria: gene performance outline filtering was
applied to exclude the lower intensity or absent values,
and only genes with fold changes larger than -2 and +2
were considered for increased/decreased expression.
The expression datasets presented in this publication have
been deposited in NCBIs Gene Expression Omnibus [15]
and are accessible through GEO Series accession number
GSE5045.
Quantitative real-time PCR
From 43 different patients, 20 biopsies, 22 primary
tumors, and 19 metastases specimens were included for
real-time PCR analysis. Due to low quantity of RNA, the
relative quantification of THBS3 was performed on 52
samples derived from 40 patients, SPARC was performed
on 55 samples derived from 43 patients, and SPP1 was
performed on 53 samples derived from 41 patients.
Total RNA was reverse-transcribed using the Gene Amp®
Gold RNA PCR Core Kit (Applied Biosystem®) according
to the manufacturer's instructions. The RT2 PCR Primer
Sets (SuperArray Bioscience Corporation®) for human
THBS3,SPARC, SPP1 (target genes) and β-actin (ACTB –
endogenous gene) were used. Real-time PCR amplifica-
tion and data analysis were performed using the ABI
Prism 7900 and 7700 HT Sequence Detector System
(Applied Biosystems®). Each sample was mixed with 24μl
of master mix (SYBR® Green PCR Master Mix – Applied
Biosystems®). The PCR conditions were 2 minutes at
50°C, 10 minutes at 95°C, followed by 40 cycles of 15
seconds at 95°C and 1 minute at 60°C. Experiments were
performed in triplicate, for both the target and the endog-
enous genes. A no-template control was included in eachBMC Cancer 2006, 6:237 http://www.biomedcentral.com/1471-2407/6/237
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amplification reaction. The PCR efficiencies of the four
genes were comparable (≥ 95%).
Real-time PCR data analysis
To determine the relative quantification of gene expres-
sion, the comparative Ct (cycle threshold) method was
used [16]. Briefly, this method uses arithmetic formulas to
determine relative quantification. To normalize the vary-
ing cDNA quantities, an endogenous control gene (β-
actin – ACTB) was run concurrently with the target gene.
For each sample, the Ct was determined for both the target
gene and the endogenous gene (median of the 3 reac-
tions). The ΔCt was determined by subtracting the ACTB
Ct from the specific target gene Ct. Identical calculations
were made for a known positive control reference sample
(QPCR Human Reference Total RNA, Stratagene, La Jolla,
CA, USA). The ΔCt of the control reference was then sub-
tracted from the ΔCt of the target gene, yielding the ΔΔCt,
and the relative quantitative value was expressed as 2-ΔΔCt.
Statistical analysis
Data analysis was performed using Minitab Statistical
Software (14.0). Clinical variables correlated with gene
expression were: age at diagnosis, gender, histological OS
subtype, site of the primary disease, metastatic status at
diagnosis, response to chemotherapy, and type of samples
(initial biopsy, primary bone tumor resection and metas-
tasis sample present at diagnosis). Overall survival was
defined as the time from diagnosis until the date of either
the last follow-up or death. The duration of event-free sur-
vival was defined as the time from diagnosis until the date
of relapse or death. If these patients had metastatic disease
at diagnosis, the event was considered as time 0. For the
relapse free survival analysis, the duration was defined as
the time from diagnosis until the occurrence of metastasis
or local relapse.
All samples from each biopsy, primary tumor resection,
and at metastasis were evaluated using gene expression
profile findings, and these variables were correlated with
survival. Overall survival, event-free survival and relapse-
free survival curves were generated by applying the Kap-
lan-Meier method, and were then compared by the log-
rank test. Continuous data were evaluated and compared
using ANOVA, Mann-Whitney or Mood's Median test.
Categorical data were studied using Chi-square or Fisher
exact tests. Statistical significance was taken as p < 0.05.
Results
A summary of the clinico-pathological parameters for
each case is detailed in Table 1. There was no significant
difference in relative expression levels of THBS3, SPARC
and SPP1 when the initial biopsy specimens, the primary
bone tumor resection specimens, and the biopsies of
metastasis were compared. Therefore we examined differ-
ential levels of gene expression of all three genes in pri-
mary tumor RNA (from both biopsy specimens and bone
tumor resections) to assess their utility as biomarkers of
prognosis. Thus in these analyses expression levels in pri-
mary tumor RNA were used as predictors of overall sur-
vival, event-free survival and relapse-free survival.
Pathway-focused GEarray® analysis
Samples from biopsy, primary tumor resection and meta-
static site (metastatic group only) from the metastatic and
non-metastatic groups were each processed for gene
expression analysis using the GEArray® Q Series Human
Tumor Metastasis Gene Array, Chemokines and Receptors
Gene Array, and Angiogenesis Gene Array. Thirty-two
genes from the angiogenesis membrane, 51 from the
tumor metastasis membrane and 25 genes from the chem-
okine membrane were identified as differentially
expressed. The values of the selected THBS3, SPARC, and
SPP1 genes are presented in Table 2. Correlation coeffi-
Table 1: Clinico-pathological description of osteosarcoma patients.
Parameter Number of patients Parameter Number of patients
Age at diagnosis (years) Huvos grade
0–10 6 I-II 27
11–20 33 III-IV 7
≥ 21 4 Not informative 9
Gender Metastasis at diagnosis
Male 25 Yes 17
Female 18 No 26
Histological subtype Site of primary disease
Osteoblastic 23 Femur 20
Chondroblastic 7 Tibia 15
Telangiectatic 4 Fibula 2
Giant cells 1 Humerus 4
Other 6 Iliac bone 1
Not informative 2 Other 1
NOTE: Mean follow-up time was 34 months (range from 2 to 83 months)BMC Cancer 2006, 6:237 http://www.biomedcentral.com/1471-2407/6/237
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cients did not detect any relationship between the relative
expression levels of these genes considered at any time
point or in combination (-0.11 < Adjusted R2 < 0.14).
THBS3 mRNA expression in osteosarcoma patients
To confirm THBS3 over-expression, we performed quanti-
tative real-time PCR on 52 samples from 40 patients. Of
the 52 tumors analyzed, 30 (58%) showed high expres-
sion of THBS3 and 22 samples (42%) showed low expres-
sion of THBS3. A comparison of the THBS3 expression
levels in biopsy versus primary tumor resection or meta-
static samples showed significant differences (p = 0.0001,
p = 0.0001, respectively). However, this correlation was
not significant in primary tumor resection samples versus
metastases (p = 0.72) (Figure 1A). In addition, different
levels of THBS3 expression were observed when biopsy
and surgical samples from the same patients were com-
pared (n = 7) (p = 0.031).
A trend for higher expression was observed in samples
from patients with metastatic disease at diagnosis (p =
0.058). However, there was no significant correlation with
other clinical parameters, such as age at diagnosis, gender,
Huvos grade, site of primary tumor, histological type and
presence of metastasis at diagnosis. Patients with OS and
high levels of expression of THBS3  in biopsy samples
stratified using the 75th percentile as cutoff value (≥ 1.0),
showed worse overall survival (p = 0.03), event-free sur-
vival (p = 0.02) and relapse free survival at diagnosis (p =
0.003) (Figure 2A). Patients containing high levels of
THBS3 expression in surgical specimens stratified using
the 50th percentile as cutoff value (≥ 0, over-expression ver-
sus down-expression), showed worse relapse free survival
(p = 0.05) (Figure 2A).
SPARC mRNA expression in osteosarcoma patients
To confirm SPARC over-expression, we performed quanti-
tative real-time PCR on 55 samples from 43 patients. High
expression of the SPARC  gene was found in 51 of 55
tumor samples (96.3%). SPARC over-expression did not
correlate with the different periods of disease (biopsy, sur-
gery and metastasis) (Figure 1B), presence of metastasis at
diagnosis, and the clinico-pathological parameters, such
as Huvos grade, age, gender, histological OS subtype, site
of primary disease, as well as, the overall survival (p =
0.81) (Figure 2B). Patients with high levels of SPARC gene
expression stratified using the 75th percentile as cutoff
value (≥ 1.5), revealed worse event-free survival (p = 0.03)
and relapse free survival (p = 0.07) (Figure 2B).
SPP1 mRNA expression in osteosarcoma patients
To confirm SPP1 over-expression, we performed quantita-
tive real-time PCR on 53 samples from 41 patients. The
SPP1  gene was over-expressed in 47 of 53 (89%) and
under-expressed in 6/53 (11%) of OS samples. In addi-
tion, there was a significantly greater level of SPP1 in
biopsy samples than in both primary tumor resections
and metastatic samples (p = 0.002, p = 0.0002, respec-
tively). However, SPP1 expression levels did not reach sig-
nificance when primary tumor resection samples were
compared to metastases (p = 0.11) (Figure 1C). A recur-
rent differential level of THBS3  expression was also
observed when comparing biopsy and primary tumor
resection samples from the same patients (n = 7) (p =
0.031). SPP1 over-expression did not correlate with the
presence of metastasis at diagnosis and the clinico-patho-
logical parameters, such as Huvos grade, age, gender, his-
tological OS subtype and site of primary disease. Patients
with OS showing high levels of expression of SPP1  in
biopsy samples, stratified using the 25th percentile as cut-
off value (≥ 1.1), revealed better overall survival (p =
0.001), event-free survival (p = 0.02) and relapse free sur-
vival (p = 0.005) (Figure 2C).
Discussion
In this study, THBS3, SPARC and SPP1 were identified by
pathway-focused GEArray®  as genes differentially
expressed in OS.
The gene for human thrombospondin 3 (THBS3) is a
member of a family that encodes an extracellular matrix
glycoprotein mediating interactions between cells and the
extracellular matrix [17,18]. The thrombospondin family
of proteins has been implicated in a number of funda-
mental biological processes: blood coagulation, embry-
onic development, tissue differentiation, tumor growth
Table 2: Pathway-focused GEArrays®: Comparison of three of the up-regulated genes in osteosarcoma samples categorized as 
metastatic at diagnosis and non-metastatic at diagnosis
Gene symbol Metastatic at diagnosis Non-metastatic at diagnosis
B/C S/C M/C B/C S/C
THBS3 23.8 53.15 7.1 AE AE
SPARC 13.4 18.6 15.3 6.8 5.0
SPP1 7.2 3.7 9.11 4.3 5.3
B, sample from biopsy, S, sample from primary tumor resection, M, sample from metastatic site, C, normal bone control, AE, absence of 
expression. The values are expressed as linear ratios against normal bone controls.BMC Cancer 2006, 6:237 http://www.biomedcentral.com/1471-2407/6/237
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and metastases, angiogenesis, nerve development, wound
healing, and inflammation [17-19].
Osteonectin (SPARC) is a 32kDa protein important for
bone calcification [20]; it is a multifunctional glycopro-
tein that belongs to the matricellular proteins, defined as
a group of extracellular regulatory macromolecules rele-
vant to the extracellular matrix structure [21]. It is
involved in a variety of biological processes including tis-
sue remodeling, cell adhesion, proliferation, differentia-
tion, matrix synthesis, angiogenesis, tumor cell migration
and invasion [22,23].
The SPP1 gene (osteopontin) is a non-collagenous bone
matrix protein with several functions, such as bone
remodeling, angiogenesis, cell adhesion, tumor migration
and invasion [24-26]. The functional diversity of oste-
opontin in bone has many features in common with the
repair processes involved in inflammatory responses [27].
It is produced by numerous cell types, osteoblasts, osteo-
clasts, T lymphocytes, NK cells and epithelial cells from
breast, kidney, skin, nerve cells and endothelial cells [24-
26].
Invasion and metastases are inherent features of malig-
nant diseases and involve both intercellular and cell-
matrix interaction. The molecular mechanisms include
transcriptional modulation of adhesive and anti adhesive
molecules, proteases and angiogenic factors [28].
As a primary tumor grows, it needs to develop a blood
supply that can support its metabolic needs – angiogen-
Relationship between gene expression and clinical evolution of disease Figure 1
Relationship between gene expression and clinical evolution of disease. The box plot shows the median, upper and lower quar-
tiles and minimum and maximum values for related gene expression. A- Relative expression of THBS3 in groups of OS patients 
represented by samples obtained from the biopsy diagnosis (n = 16), primary tumor surgery (n = 19) and metastases (n = 
17) ; B- Relative expression of SPARC in groups of OS patients represented by samples obtained from the biopsy diagnosis (n 
= 26), primary tumor surgery (n = 16) and metastases (n = 13); C- Relative expression of SPP1 in groups of OS patients rep-
resented by samples obtained from the biopsy diagnosis (n = 16), primary tumor surgery (n = 20) and metastases (n = 17).BMC Cancer 2006, 6:237 http://www.biomedcentral.com/1471-2407/6/237
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esis. These new blood vessels may also provide an escape
route by which cells can leave the tumor and enter into the
body's circulatory blood system, a process known as
"intravasation". The cells need to survive in the circulation
until they are arrested in a new organ; where they may
extravasate from the circulation into the surrounding tis-
sue. Once in the new site, cells must initiate and maintain
growth to form pre-angiogenic micrometastases; this
growth must be sustained by the development of new
blood vessels in order to form a macroscopic tumor [6].
Thrombospondin 3 is structurally similar to cartilage oli-
gomeric matrix protein (COMP/THBS5), but its function
is unknown. A study in THBS3-null mice provided evi-
dence for the role of THBS3 in the regulation of skeletal
maturation in mice [29]. The role of THBS1, the most
widely studied gene in this family, in angiogenesis and
tumor progression remains controversial. THBS1  has
been considered an inhibitor of angiogenesis and tumor
progression in bladder and lung cancer [30,31]. In con-
trast, it has also been considered a stimulator of both
processes in pancreatic carcinoma, melanoma and hepa-
tocellular carcinoma [32-34]. One study found high
THBS1  levels in hepatocellular carcinoma and venous
invasion in tumors with low levels of vascular endothelial
growth factor (VEGF) protein expression [34].
The group with metastasis at diagnosis showed high levels
of THBS3 expression in biopsy samples, demonstrating
the importance of this gene in tumor growth and progres-
sion. These data strongly suggest that high THBS3 expres-
sion can predict worse overall survival, event-free survival
and relapse free survival at diagnosis. After chemotherapy,
levels of THBS3 declined in some tumors. The groups of
patients who maintain over expression have worse relapse
free survival, suggesting that keeping THBS3 at high levels
maintains the capacity of angiogenesis activated by
THBS3. This is part of the process of tumor progression
and perhaps may be used as a prognostic factor and ther-
apeutic target in OS.
To the best of our knowledge, this is the first report about
the THBS3 gene function as a stimulator of tumor progres-
sion in osteosarcoma. Its effects, like those of THBS1, may
Overall, event-free survival and relapse-free survival analyses of OS patients correlated with gene expression profiling of either  biopsy or primary tumor resection onset groups Figure 2
Overall, event-free survival and relapse-free survival analyses of OS patients correlated with gene expression profiling of either 
biopsy or primary tumor resection onset groups. A- Overall, event-free survival and relapse-free survival of biopsy onset 
group with over-expression of THBS3, and relapse-free survival of primary tumor resection onset group with over-expression 
of THBS3. B- Overall, event-free survival and relapse-free survival of biopsy onset group with over-expression of SPARC.C- 
Overall, event-free survival and relapse-free survival of biopsy onset group with over-expression of the SPP1 gene.
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also depend on concentration, type of domain activated
or available, and type of receptors present on endothelial
cells [33,35,36]. The study of these parameters together
with the expression levels of THBS3 in OS should be con-
sidered, given one's interest in anti-angiogenic agents in
the OS treatment protocol.
Osteonectin is produced by osteoblasts and young osteo-
cytes [37]. SPARC is expressed at high levels in bone tissue
[38].
In this study no differences were observed between the
levels of expression in biopsy, primary tumor resection
and metastatic site samples, showing that high levels of
SPARC are not required for tumor progression. However,
higher SPARC expression (≥ 1.5) has worse event-free sur-
vival and shows a tendency to early relapse free survival.
This strongly suggests that SPARC expression is necessary
for tumor growth and maintenance, and may be used as a
promising prognostic marker in OS.
Over-expression of SPARC promotes tumor growth and
was reported in a variety of human malignancies, includ-
ing melanoma, breast cancer, esophageal cancer and gas-
tric carcinoma [28,39-41], but other reports suggest that
decreased SPARC expression is associated with increased
tumorigenesis and metastases in human ovarian carci-
noma and neuroblastoma [42,43]. The promoting or
inhibiting effects of osteonectin in different cancers seem
dependent upon the cell type, the concentration, and the
presence of full-length or proteolytic fragments of
osteonectin [44].
Osteopontin (SPP1) is a major protein of the extracellular
bone matrix, and gene expression is up regulated in spe-
cific phases of osteoblastic lineage differentiation [45-47].
SPP1 has become of interest in tumorigenesis, and expres-
sion of the protein has been observed in human cancer
[48].
In this study, we observed that biopsy samples had higher
expression of SPP1  than samples from primary tumor
resection and metastasis, showing that high levels of SPP1
are not necessary for tumor progression in OS. At the same
time, we noticed that the level of expression is an inde-
pendent variable from the presence of metastatic disease
at diagnosis; these two characteristics indicate that high
expression of SPP1 is not necessary for tumor progression
or metastatic disease in OS. In contrast, high expression of
SPP1 in other tumors, such as breast cancer, lung cancer,
prostate cancer, hepatocellular carcinoma, colon cancer
has been associated with tumor progression and metas-
tases [49-52]. Another contrast is that we observed over
expression of SPP1 correlates with better overall survival,
event-free survival and relapse free survival. A study of 57
samples from OS patients by immunohistochemistry
reported over expression of SPP1 and VEGF. However,
SPP1 levels showed no correlation with overall survival
and event-free survival. SPP1 is normally expressed in nor-
mal bone and, as part of the inflammatory response, par-
ticipates in the remodeling process of the bone [53]. The
functional diversity of SPP1  in bone formation and
remodeling appears to be related to the fundamental roles
of this protein in host defense and tissue repair; in fact, the
bone remodeling process has many features in common
with the repair processes involved in inflammatory
responses [27].
Identification of the molecular determinants of invasion
and metastatic pathways will guide the development of a
rational strategy for devising specific therapies that target
the pathways leading to OS.
Conclusion
In conclusion, through the screening of arrays we identi-
fied genes related to tumorigenesis. Three genes were val-
idated with real-time RT-PCR and correlated with clinico-
pathological parameters; whereby the clinical significance
of over expression of THBS3 for tumor growth and pro-
gression, the necessity of SPARC for tumor growth and
maintenance, and the potential for SPP1 as a biological
marker of OS were demonstrated.
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